| 1. |
Fernández-Martos C, Pericay C, Aparicio J, et al. Phase Ⅱ, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol, 2010, 28(5): 859-865.
|
| 2. |
Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol, 2015, 16(8): 957-966.
|
| 3. |
Glynne-Jones R, Hughes R. Critical appraisal of the 'wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg, 2012, 99(7): 897-909.
|
| 4. |
Ludmir EB, Palta M, Willett CG, et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer, 2017, 123(9): 1497-1506.
|
| 5. |
Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol, 2011, 29(23): 3163-3172.
|
| 6. |
Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(suppl_4): i22-i40.
|
| 7. |
Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 1997, 12(1): 19-23.
|
| 8. |
Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol, 2014, 32(15): 1554-1562.
|
| 9. |
Bouzourene H, Bosman FT, Seelentag W, et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer, 2002, 94(4): 1121-1130.
|
| 10. |
Battersby NJ, Moran B, Yu S, et al. MR imaging for rectal cancer: the role in staging the primary and response to neoadjuvant therapy. Expert Rev Gastroenterol Hepatol, 2014, 8(6): 703-719.
|
| 11. |
Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol, 2011, 29(28): 3753-3760.
|
| 12. |
Siddiqui MR, Bhoday J, Battersby NJ, et al. Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. World J Gastroenterol, 2016, 22(37): 8414-8434.
|
| 13. |
Patel UB, Brown G, Rutten H, et al. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann Surg Oncol, 2012, 19(9): 2842-2852.
|
| 14. |
van den Broek JJ, van der Wolf FS, Lahaye MJ, et al. Accuracy of MRI in restaging locally advanced rectal cancer after preoperative chemoradiation. Dis Colon Rectum, 2017, 60(3): 274-283.
|
| 15. |
Sclafani F, Brown G, Cunningham D, et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. Br J Cancer, 2017, [Epub ahead of print].
|
| 16. |
Seierstad T, Hole KH, Gr?holt KK, et al. MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer. Br J Radiol, 2015, 88(1051): 20150097.
|
| 17. |
Yu SK, Tait D, Chau I, et al. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy? Int J Radiat Oncol Biol Phys, 2013, 87(3): 505-511.
|
| 18. |
Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol, 2014, 32(1): 34-43.
|
| 19. |
Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia, 2009, 11(2): 102-125.
|
| 20. |
Dijkhoff RAP, Beets-Tan RGH, Lambregts DMJ, et al. Value of DCE-MRI for staging and response evaluation in rectal cancer: a systematic review. Eur J Radiol, 2017, 95: 155-168.
|
| 21. |
Blazic IM, Campbell NM, Gollub MJ. MRI for evaluation of treatment response in rectal cancer. Br J Radiol, 2016, 89(1064): 20150964.
|
| 22. |
Fusco R, Petrillo M, Granata V, et al. Magnetic resonance imaging evaluation in neoadjuvant therapy of locally advanced rectal cancer: a systematic review. Radiol Oncol, 2017, 51(3): 252-262.
|
| 23. |
H?tker AM, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI of rectal cancer in the assessment of response to therapy: a systematic review. Dis Colon Rectum, 2014, 57(6): 790-799.
|
| 24. |
Joye I, Deroose CM, Vandecaveye V, et al. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol, 2014, 113(2): 158-165.
|
| 25. |
Xie H, Sun T, Chen M, et al. Effectiveness of the apparent diffusion coefficient for predicting the response to chemoradiation therapy in locally advanced rectal cancer: a systematic review and meta-analysis. Medicine (Baltimore), 2015, 94(6): e517.
|
| 26. |
Curvo-Semedo L, Lambregts DM, Maas M, et al. Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy－conventional MR volumetry versus diffusion-weighted MR imaging. Radiology, 2011, 260(3): 734-743.
|
| 27. |
Lee MA, Cho SH, Seo AN, et al. Modified 3-point MRI-based tumor regression grade incorporating DWI for locally advanced rectal cancer. AJR Am J Roentgenol, 2017, [Epub ahead of print].
|
| 28. |
Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol, 2007, 188(6): 1622-1635.
|
| 29. |
Lambregts DM, Beets GL, Maas M, et al. Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol, 2011, 21(12): 2567-2574.
|
| 30. |
Engin G, Sharifov R, Güral Z, et al. Can diffusion-weighted MRI determine complete responders after neoadjuvant chemoradiation for locally advanced rectal cancer? Diagn Interv Radiol, 2012, 18(6): 574-581.
|
| 31. |
Gollub MJ, Tong T, Weiser M, et al. Limited accuracy of DCE-MRI in identification of pathological complete responders after chemoradiotherapy treatment for rectal cancer. Eur Radiol, 2017, 27(4): 1605-1612.
|
| 32. |
Phongkitkarun S, Tohmad U, Larbcharoensub N, et al. DCE-MRI-derived parameters as predictors of response to neo-adjuvant chemoradiation treatment of rectal carcinoma. J Med Assoc Thai, 2016, 99(3): 338-347.
|
| 33. |
Liu Z, Zhang XY, Shi YJ, et al. Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clin Cancer Res, 2017, [Epub ahead of print].
|
1/5
WeChat